In April 2021, loncastuximab tesirine (lonca), a first-in-class CD19-directed antibody-drug conjugate, was approved for the treatment of R/R DLBCL after ≥2 prior lines of systemic therapy in the United States (USA). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.